



2016 Alliance Fall Group Meeting
Loews Chicago O'Hare Hotel – Rosemont, IL
May 12th 2017
3-5 PM

Pharmacogenetics and Population Pharmacology Meeting Agenda

Chair(s): Mark J. Ratain
Vice-Chairs: Howard L McLeod and Lionel D. Lewis

Time	Description	Presenter
3:00 PM:	Welcome and Introductions	McLeod /Lewis
	Pharmacogenomics updates/new studies	H.L. McLeod
3:05-3:25	Genetic biomarkers of thrombotic risk in African-American cancer patients.	Jamie Brewer, MD.
3:25-3:45	Pharmacogenetics of tamoxifen and endoxifen.	Dan L. Hertz PharmD, PhD
3:45 -4:00	A011203 – A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, Breast Cancer: PK Update.	Joel Reid PhD
	Population Pharmacology	LD Lewis
4:00-4:30	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castrate resistant prostate cancer (CRPC):	Russell Smulewitz, MD
4:30 - 4:45	A031201 Enzalutamide vs Enzalutamide + Abi in metastatic CRPC- Update	Lionel Lewis MD Jan H Beumer PhD, PharmD
4:45	Adjourn	